{
  "symbol": "REGN",
  "year": 2025,
  "period": "Q2",
  "curated_text": "Symbol: REGN. Year: 2025. Period: Q2. ReportType: Q10. Section: Competition and Market Position. This section discusses competitors, market dynamics, and regulatory landscape.  Competitors mentioned: New Indications, Dupixent, Regeneron, Total Sanofi, Bayer, Change Research, 265.5, 26.1 0.1 Dupixent, 19.8 Total, FDA. Context excerpt: competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our products and product candidates is subject to significant competition - Marketed Products.\" In addition, if independent not-for-profit patient assistance funds that provide copay assistance are unable to support eligible patients, this will likely have a continued negative impact on patient affordability resulting in lower utilization of higher-cost anti-VEGF agents. 35 Table of Contents Collaboration Revenue Sanofi Collaboration Revenue Three Months Ended March 31, (In millions) 2025 2024 Regenero",
  "competition_summary": [
    {
      "competitor": "New Indications",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "Dupixent",
      "mentions": 6,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "Regeneron",
      "mentions": 10,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "Total Sanofi",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "Bayer",
      "mentions": 2,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "Change Research",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "265.5",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "26.1 0.1 Dupixent",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "19.8 Total",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    },
    {
      "competitor": "FDA",
      "mentions": 1,
      "context": "competition from other anti-VEGF products, including biosimilars, as well as the transition of patients from EYLEA to EYLEA HD.\u00a0The magnitude and duration of such impact is presently unknown. For more information, see Part I, Item 1A. \"Risk Factors - Risks Related to Commercialization of Our Marketed Products, Product Candidates, and New Indications for Our Marketed Products - We are substantially dependent on the success of EYLEA, EYLEA HD, and Dupixent \" and \" The commercial success of our pro"
    }
  ]
}